Theranostic agents targeting PSMA and, notably, 68Ga-PSMA-617 represent new tools of the therapeutic arsenal against metastatic breast cancer, since PSMA-based PET/CT imaging, which is now available in clinical practice is the procedure of choice in case of recurrence of prostate cancer [9,85,86]. The gene discussed is FOLH1; the disease is Familial prostate cancer.